Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for HCC Prevention in Cirrhosis
NCT02273362Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2014
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining). Started Nov 2014; status: completed.
02
Drugs
erlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02273362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273362.